Idiopathic pulmonary fibrosis

Česká verze

Authors: M. Doubková; J. Skřičková
Authors place of work: Klinika nemocí plicních a tuberkulózy Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Jana Skřičková, CSc.
Published in the journal: Vnitř Lék 2005; 51(12): 1375-1384
Category: Přehledný referát

Summary

Idiopathic pulmonary fibrosis (IPF), known in Europe as cryptogenic fibrosing alveolitis, is a rare, progressive and usually fatal form of idiopathic interstitial pneumonia. IPF is characterized by failure of alveolar re-epithelization, persistence of fibroblasts, deposition of extracellular matrix, and distortion of lung architecture which ultimately results in respiratory failure. Current consensus statements reserve the term IPF to refer to a specific clinical entity associated with the histopatological pattern of usual interstitial pneumonia (UIP). UIP is characterized by temporal heterogeneity, with alternating areas of interstitial fibrosis, fibroblastic foci (areas of proliferating fibroblasts and myofibroblasts), inflammation, honeycomb lung, and normal parenchyma. Fibroblastic foci are associated with progressive disease. Treatment of IPF remains clinical problem. Currently, there is no conservative therapy improving the survival of patients. Lung transplantation, however, improves survival. Identification of pathways crucial to fibrogenesis might offer potentially novel therapeutic targets to slow or halt progression of IPF.

Key words:
fibrogenesis - idiopathic interstitial pneumonia - pulmonary fibrosis - treatment

Zdroje

1. American Thoracic Society/European Respiratory Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.

2. American Thoracic Society/European Respiratory Society: International multidisciplinary consensus classification of the idiopathic intersticial pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.

3. Antoniou KM, Ferdoutsis E, Bouros D et al. Interferons and their application in the lung. Chest 2003; 123: 209-216.

4. Bourke SC, Clague H. Review of cryptogenic fibrosing alveolitis, including current treatment guidelines. Postgrad Med J 2000; 76: 618-624.

5. Coultas DB, Zumwalt RE, Black WC et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.

6. Crystal RG, Bitterman PB, Mossman B et al. Future research directions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 236-246.

7. Cushley M, Davidson A, Du Bois R et al. Diagnosis and assessment of diffuse parenchymal lung disease. Thorax 1999; 54(Suppl): 1-30.

8. Davies HR, Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002; 1: 211-224.

9. Davies HR, Richeldi L, Walters EH et al. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2003; 3: CD003134.

10. Demedts M, du Bois RM, Nemery B et al. Interstitical lung diseases: a clinical update. Eur Respir J 2001; 18: 1S-133S.

11. Dunsmore SE, Shapiro SD The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J Clin Invest 2004; 113: 180-182.

12. Fišerová J, Chlumský J, Satinská J et al. Funkční vyšetření plic. GEUM, Praha, 2003.

13. Flaherty KR, Colby TV, Travis WD et al. Fibroblastic foci in usual interstitial pneumonia. Am J Respir Crit Care Med 2003; 167: 1410-1415.

14. Flaherty KR, Thwaite EL, Kazeorooni EA et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58: 143-148.

15. Flaherty KR, Toews GB, Lynch III JP et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110: 278-282.

16. Gazdík F, Zubo I, Gazdíková K. Imunologické mechanizmy při vybraných intersticiálnych pľúcnych procesoch. Stud Pneumol Phthiseol 2003; 63: 199-207.

17. Green FHY. Overview of pulmonary fibrosis. Chest 2002; 122: 334S-339S.

18. Hamman L, Rich AR. A clinical-pathological conference. A case of heart failure. International Clinics., 43rd series, 1933, 1: 197-232.

19. Hamman L, Rich AR. Fulminant diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51: 154-163.

20. Hamman L, Rich AR. Acute difuse interstitial fibrosis of the lung. Bull. Johns Hopkins Hosp 1944; 74: 177-212.

21. Hanáček J. Patofyziológia intersticiálnych pľúcných chorob. Stud Pneumol Phthiseol 1999; 59: 246-254.

22. Homolka J, Altmann V, Votava V. Increasing prevalence of idiopatic pulmonary fibrosis in the Czech Republic. Chest 1999; 116(Suppl. 2): 155.

23. Homolka J, Votava V. Intersticiální plicní procesy. Praha: Maxdorf 1999.

24. Ionaga K, Miyajima M, Suga M et al. Alteration in cytokeratin expression by the alveolar lining epithelial cells lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol 1997; 182: 217-224.

25. Kaminski N, Belperio JA, Bitterman PB et al. Idiopathic pulmonary fibrosis, suplement. Am J Respir Cell Mol Biol 2003; 29: 1S-105S.

26. Katzenstein AA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.

27. Khahil N, O´Connor R Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. Can Med Assoc J 2004; 171: 153-160.

28. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia in the 1981 - 1990. L´internista 1995; 3: 105-108.

29. Kolek V. Diagnostika a léčba idiopatických intersticiálních pneumonií. Respirace 2001; 7: 98-104.

30. Kolek V, Lenhart K, Bártová A. Imunogenetické aspekty kryptogenní fibrotizující alveolitidy. Stud Pneumol Phthiseol 1997; 57: 104-105.

31. Kolek V, Žurková M, Petřek M et al. Klinické zkušenosti s idiopatickou plicní fibrózou ve vztahu k nové klasifikaci. Stud Pneumol Phthiseol 2000; 60: 168-170.

32. Kotton DN, Ma BY, Cardoso WV et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001; 128: 5181-5188.

33. Kuhn C, McDonald JA The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastruktural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138: 1257-1265.

34. Levinský L, Houštěk J, Hloušková Z et al. Prevalence idiopatické difusní intersticiální plicní fibrosy v ČSSR (Československu). Česk Pediatr 1974; 29: 353-357.

35. Liebow A. Definition and classification of interstitial pneumonias in human pathology. Prog Resp Res 1975; 8: 1-33.

36. Marshall RP, Puddicombe A, Cookson WO et al. Adult familial cryptogenic fibrosing alveolitis in United Kingdom. Thorax 2000; 55: 143-146.

37. Meyers BF, Lynch JP, Turlock EP et al. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-yer institutional experience. J Thorax Cardiovsc Surg 2000; 120: 99-107.

38. Millar A. Anti-cytokine therapy in fibrosing alveolitis: where are we now? Respir Res 2000; 1: 3-5.

39. Nicholson AG, Colgy TV, du Bois RM et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162: 2213-2217.

40. Panos RJ, Mortenson RL, Niccoli SA et al. Clinical deterioration in patiens with idiopathic pulmonary fibrosis: cause and assessment. Am J Med 1990; 88: 396-404.

41. Polák J, Homolka J, Vašáková M et al. High-resolution počítačová tomografie v diagnostice kryptogenní fibrotizující alveolitidy. Korelace s plicním funkčním vyšetřením a bronchoalveolární laváží. Čas Lék Česk 1996; 135: 417-422.

42. Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.

43. Ramos C, Montano M, Garcia-Alvarez J et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growt rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24: 591-598.

44. Reynolds HY, Newball HH Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974; 84: 559-573.

45. Richeldi L, Davies HR, Ferrara G et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2004; 4: CD002880.

46. Sandoz E. Über zwei Fälle von „fötaler Bronchektasie“. Thesis (doctoral). Bern: Universität Bern 1906.

47. Satinská J. Význam funkčního vyšetřování u chronické obstrukční plicní nemoci. Vnitř Lék 2004; 50: 670-674.

48. Selman M, King TE, Pardo A et al. Idiopathic pulmonary fibrosis: prevailing a evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151.

49. Selman M, Thannickal VJ, Pardo A et al. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004; 64: 405-430.

50. Skřičková J. Diferenciální diagnostika pneumonií z pohledu klinika. In: Ševčík P, Skřičková J, Šrámek V et al. Záněty plic v intenzivní medicíně. Praha: Galén 2004: 49-59.

51. Strieter RM, Starko KM, Enelow RI et al. Effects of interferon-γ1b on biomarker expression in patients with idiopathic pulmoary fibrosis. Am J Respir Crit Care Med 2004; 170: 133-140.

52. Turner-Warwick M, Burrows B, Johson A et al. Cryptogenic fibrosin alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980; 35: 593-599.

53. Uhal BD, Joshi I, True AL et al. Fibroblasts isolated after fibrotic lung injury induce apoptosisi of alveolar epithelial cells in vitro. Am J Physiol 1995; 269: L819-L828.

54. Vašáková M. Idiopatická plicní fibróza (kryptogenní fibrotizující alveolitida). In: Zatloukal P, Fiala P, Votruba J et al. Vnitřní lékařství. Díl IIIa. Pneumologie. Praha: Galén 2001: 145-149.

55. Votava V, Svobodová L, Homolka J. Intersticiální plicní procesy (přehledný článek). Čas Lék Čes 2002; 141: 445-448.

56. Vyšehradský R. Farmakoterapia kryptogénnej fibrotizujúcej alveolitidy. Stud Pneumol Phthiseol 2001; 61: 195-198.

57. Walker GA, Guerrero IA, Leinwand LA et al. Myofibroblasts: molecular crosscressers. Curr Top Dev Biol 2001; 51: 91-107.

58. Wang R, Ramos C, Joshi I et al. Human lung myofibrobalst-derived inducers of alveolar eppithelial apoptosis identified as angiotensin peptides. Am J Physiol 1999; 277: L1158-L1164.

59. White ES, Lazar MH, Thannickal VJ. Pathogenetic mechanism in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003; 201: 343-354.